Aspen Clinical Research is currently taking part in a clinical research study investigating the effects of an oral investigational medication designed to help treat Parkinson’s Disease by the prevention of dopaminergic neurodegeneration and anti-inflammatory effects. Participants in this study must be 30 through 79 years of age and:
- Be newly diagnosed with Parkinson’s Disease and not taking any Parkinsonian Disease Medication OR
- Be taking Amantadine or other Anticholinergic Medications for 4 weeks prior to screening for study participation.
Your first visit to the research clinic will be a screening visit. During this visit you will meet with a study coordinator to fully review study details. If you decide to participate, a more in-depth assessment of your health will take place to determine your final eligibility. If you are eligible and choose to enroll, you will be required to return to our research clinic at various times for treatment and follow-up visits.
Space in the study is limited. Health insurance is not required. All clinical visits, medications, and physical exams are provided to you at no cost. You may be compensated for the time and travel involved in this study.
Please complete the form below to see if you pre-qualify for the study. All information you provide to Aspen Clinical Research will remain strictly confidential.
Disclaimer: Not all individuals that complete the online questionnaire will qualify for the study. An in-depth study and medical evaluation must be completed in person in order to qualify for the study.